title: Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment.
abstract: OBJECTIVE
  This is our final report on the clinical effectiveness and safety of long-term pantoprazole in patients with severe peptic ulcer or reflux disease during continuous treatment for up to 5 years.
  
  
  METHODS
  Patients (n= 150) with peptic ulcer or reflux erosive oesophagitis running an aggressive course or with complications, and refractory to H2-receptor antagonists, were entered into this 5-year programme. Assessment was by serial endoscopy, clinical examination, serum gastrin estimation, gastric mucosal histology and mucosal endocrine cell quantification.
  
  
  RESULTS
  Healing results were presented earlier. The estimated rates of remission on maintenance treatment with pantoprazole (n = 115) were 82% at 1 year, 75% at 2 years, 72% at 3 years, 70% at 4 years and 68% at 5 years. Helicobacter pylori infection appeared not to influence the outcome in reflux patients, with roughly two-thirds continuing in remission irrespective of infection. Only four patients had adverse events considered to be definitely related to pantoprazole. Median gastrin levels rose by 1.5-2-fold and were higher in those with H. pylori infection; 13 patients had levels >500 ng/L on at least one occasion, but these high levels were not sustained. Histological changes were more marked in patients infected with H. pylori: chronic gastritis decreased in the antrum and increased in the corpus, which also showed atrophic changes. The total number of endocrine cells in the antrum showed little variation over 60 months but fell by around one-third in the corpus.
  
  
  CONCLUSIONS
  Long-term treatment with pantoprazole is effective and safe.
authors.affiliation: Rotherham General Hospitals NHS Trust, Rotherham S60 2UD, UK. bardhan.sec@rothgen.nhs.uk
authors.forename: K D
authors.initials: KD
authors.lastname: Bardhan
authors.forename: A E
authors.initials: AE
authors.lastname: Bishop
authors.forename: J M
authors.initials: JM
authors.lastname: Polak
authors.forename: H M
authors.initials: HM
authors.lastname: Romanska
authors.forename: A
authors.initials: A
authors.lastname: Rowland
authors.forename: M
authors.initials: M
authors.lastname: Thompson
authors.forename: P
authors.initials: P
authors.lastname: Morris
authors.forename: S
authors.initials: S
authors.lastname: Schaefer-Preuss
authors.forename: R
authors.initials: R
authors.lastname: Luehmann
authors.forename: B
authors.initials: B
authors.lastname: McCaldin
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002452:Cell Count; D019858:Enteroendocrine Cells; D005260:Female; D005753:Gastric Mucosa / Q000166:cytology; D019863:Gastrin-Secreting Cells; D005755:Gastrins / Q000097:blood; D005756:Gastritis / Q000188:drug therapy; D016481:Helicobacter Infections / Q000097:blood / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000077402:Pantoprazole; D010437:Peptic Ulcer / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D013454:Sulfoxides / Q000627:therapeutic use*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D005755:Gastrins; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole